Advertisement

Antifungal Management

  • S. Rinaldi
  • A. R. De Gaudio

Abstract

During the last 2 decades, an increased frequency of severe life-threatening infections caused by yeasts has been reported in critical ICU patients [1]. The two main factors contributing to yeast infections are: the disregulation of immune system and the alteration of microbial flora secondary to extensive use of broad-spectrum antibiotics. Critically ill patients exhibit a complex change in immune function characterized by deactivation of macrophages and altered cellular response with shift from Th1 to Th2 response [1, 2]. Many other factors impairing the immune function during critical illness include hyperglycemia and the use of corticosteroids [2]. In particular, corticosteroids have profound effects on the distribution and function of neutrophils, monocytes, and lymphocytes and they directly stimulate the growth of some yeasts like Aspergillus fumigatus that have sterol binding proteins [2]. In ICU the two main fungal species involved in severe invasive infections are Candida spp. and Aspergillus spp., while Cryptococcus spp. remains a significant pathogen only in patients with severe immunodepression like those affected by HIV [1]. Invasive candidiasis affects around 2% of ICU patients in the USA, causing around 10% of ICU-acquired bloodstream infections and representing the third commonest blood-stream pathogen [1]. However, the epidemiology of candidemia depends upon geographic region, ICU type, and case mix. The crude mortality associated with candidemia ranges between 40 and 70%, depending on the severity of the underlying disease, while attributable mortality estimates vary between 20 to 50% from retrospective studies and 5–7% from prospective clinical trials [3].

Keywords

Antifungal Therapy Invasive Aspergillosis Invasive Fungal Infection Invasive Candidiasis Candida Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schelenz S (2008) Management of candidiasis in the intensive care unit. J Antimicrobial Chemother 61:i31–i34CrossRefGoogle Scholar
  2. 2.
    Trof RJ, Beishuizen A, Debets-Ossenkopp YJ et al (2007) Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Med 33:1694–1703CrossRefPubMedGoogle Scholar
  3. 3.
    Marie M, Oscar M, Thierry C (2008) Bench-to-bedside review: candida infections in the intensive care unit. Crit Care 12:204CrossRefGoogle Scholar
  4. 4.
    Leroy O, Gangneux JP, Montravers P et al for the Amar Cand Study Group (2009) Epidemiology, management, and risk factors for death of invasive candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006). Crit Care Med 37(5):1612–1618CrossRefPubMedGoogle Scholar
  5. 5.
    Fluit AC, Jones ME, Schmitz FJ et al (2000) Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 30:454–460CrossRefPubMedGoogle Scholar
  6. 6.
    Kibbler CC, Seaton S, Barnes RA et al (2003) Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 54:18–24CrossRefPubMedGoogle Scholar
  7. 7.
    Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E (2007) Invasive aspergillosis in the intensive care unit. Clin Infect Dis 45(2):205–216CrossRefPubMedGoogle Scholar
  8. 8.
    Leon C, Ruiz-Santana S, Saavedra P et al (2006) A bedside scoring system (‘Candida score’) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 34:730–737CrossRefPubMedGoogle Scholar
  9. 9.
    Ostrosky-Zeichner L, Sable C, Sobel J et al (2007) Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 26:271–276CrossRefPubMedGoogle Scholar
  10. 10.
    Pittet D, Monod M, Suter PM et al (1994) Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 220:751–758CrossRefPubMedGoogle Scholar
  11. 11.
    Reiss E, Morrison CJ (1993) Nonculture methods for diagnosis of disseminated candidiasis. Clin Microbiol Rev 6:311–323PubMedGoogle Scholar
  12. 12.
    Bar W, Hecker H (2002) Diagnosis of systemic candida infections in patients of the intensive care unit. Significance of serum antigens and antibodies. Mycoses 45:22–28CrossRefPubMedGoogle Scholar
  13. 13.
    Sendid B, Poirot JL, Tabouret M et al (2002) Combined detection of mannanamia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J Med Microbiol 51:433–442CrossRefPubMedGoogle Scholar
  14. 14.
    Ostrosky-Zeichner L, Alexander BD, Kett DH et al (2005) Multicenter clinical evaluation of the (1,3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41:654–659CrossRefPubMedGoogle Scholar
  15. 15.
    Morace G, Pagano L, Sanguinetti M et al (1999) PCR-restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hematological malignancies. J Clin Microbiol 37:1871–1875PubMedGoogle Scholar
  16. 16.
    Ascioglu S, Rex JH, de Pauw B et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 34:7–14CrossRefPubMedGoogle Scholar
  17. 17.
    Vandewoude KH, Blot SI, Depuydt P et al (2006) Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 10:R31CrossRefPubMedGoogle Scholar
  18. 18.
    Andreas S, Heindl S, Wattky C et al (2000) Diagnosis of pulmonary aspergillosis using optical brighteners. Eur Respir J 15:407–411CrossRefPubMedGoogle Scholar
  19. 19.
    Greene R (2005) The radiological spectrum of pulmonary aspergillosis. Med Mycol 43:S147–S154CrossRefPubMedGoogle Scholar
  20. 20.
    Ostrosky-Zeichner L, Alexander BD, Kett DH et al (2005) Multicenter clinical evaluation of the (1→3) beta-D glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 41:654–659CrossRefPubMedGoogle Scholar
  21. 21.
    Digby J, Kalbfleisch J, Glenn A et al (2003) Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 10:882–885PubMedGoogle Scholar
  22. 22.
    Raad I, Hanna H, Huaringa A et al (2002) Diagnosis of invasive pulmonary aspergillosis using polymerase chain reaction-based detection of Aspergillus in BAL. Chest 121:1171–1176CrossRefPubMedGoogle Scholar
  23. 23.
    Playford EG, Eggimann P, Calandra T (2008) Antifungals in the ICU. Curr Opin Infect Dis 21:610–619CrossRefPubMedGoogle Scholar
  24. 24.
    Noskin GA, Pietrelli L, Coffey G et al (1998) Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients. Clin Infect Dis 26:461–467CrossRefPubMedGoogle Scholar
  25. 25.
    Rex JH, Bennett JE, Sugar AM et al (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 331:1325–1330CrossRefPubMedGoogle Scholar
  26. 26.
    Pfaller MA, Diekema DJ, Gibbs DL et al (2007) Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 45:1735–1745CrossRefPubMedGoogle Scholar
  27. 27.
    Kullberg BJ, Sobel JD, Ruhnke M et al (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised noninferiority trial. Lancet 366:1435–1442CrossRefPubMedGoogle Scholar
  28. 28.
    Vazquez JA, Skiest DJ, Nieto L et al (2006) A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 42:1179–1186CrossRefPubMedGoogle Scholar
  29. 29.
    Wilcox CM, Darouiche RO, Laine L et al (1997) A randomized, double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J Infect Dis 176:227–232CrossRefPubMedGoogle Scholar
  30. 30.
    Gauthier GM, Nork TM, Prince R et al (2005) Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 41:e27–e28CrossRefPubMedGoogle Scholar
  31. 31.
    Mora-Duarte J, Betts R, Rotstein C et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020–2029CrossRefPubMedGoogle Scholar
  32. 32.
    Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 49:3640–3645CrossRefPubMedGoogle Scholar
  33. 33.
    Garey KW, Rege M, Pai MP et al (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infects Dis 43:25–31CrossRefGoogle Scholar
  34. 34.
    Ayeni O, Riederer KM, Wilson FM, Khatib R (1999) Clinicians’ reaction to positive urine culture for Candida organisms. Mycoses 42(4):285–289CrossRefPubMedGoogle Scholar
  35. 35.
    Garey KW, Neuhauser MM, Bearden DT et al (2006) Evaluation of antifungals in the surgical intensive care unit: a multiinstitutional study. Mycoses 49:226–231CrossRefPubMedGoogle Scholar
  36. 36.
    Pfaller MA, Diekema DJ, Jones RN et al (2001) International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 39:3254–3259CrossRefPubMedGoogle Scholar
  37. 37.
    Pappas PG, Rex JH, Sobel JD et al (2004) Guidelines for treatment of candidiasis. Clin Infect Dis 38:161–189CrossRefPubMedGoogle Scholar
  38. 38.
    Bohme A, Ruhnke M, Buchheidt D et al (2003) Treatment of fungal infections in hematology and oncology—Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82:S133–S140CrossRefPubMedGoogle Scholar
  39. 39.
    Herbrecht R, Denning DW, Patterson TF et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408–415CrossRefPubMedGoogle Scholar
  40. 40.
    Fluckiger U, Marchetti O, Bille J et al (2006) Treatment options of invasive fungal infections in adults. Swiss Med Wkly 136:447–463PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • S. Rinaldi
    • 1
  • A. R. De Gaudio
    • 1
  1. 1.Department of Critical Care, Section of Anesthesiology and Intensive CareUniversity of FlorenceFlorenceItaly

Personalised recommendations